Compare VMAR & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VMAR | ENSC |
|---|---|---|
| Founded | 1995 | 2003 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6M | 1.7M |
| IPO Year | 2020 | N/A |
| Metric | VMAR | ENSC |
|---|---|---|
| Price | $1.47 | $0.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 994.2K |
| Earning Date | 04-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $55.01 |
| Revenue Next Year | N/A | $1,033.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $0.23 |
| 52 Week High | $7.07 | $2.75 |
| Indicator | VMAR | ENSC |
|---|---|---|
| Relative Strength Index (RSI) | 51.48 | 48.76 |
| Support Level | $1.23 | $0.23 |
| Resistance Level | $2.10 | $0.32 |
| Average True Range (ATR) | 0.32 | 0.02 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 35.36 | 51.93 |
Vision Marine Technologies Inc designs and manufactures electric outboard powertrain systems, power boats, related technology, and rents electric boats. Its models include Bruce 22, Fantail 217, VX Electric Pontoon, Volt 180, Phantom, and others. The company provides goods and services for the recreational boating market and focuses on electric outboard powertrain systems, electric power boats, and the renting of electric boats through its subsidiary. It sells boats, parts, and accessories and offers services related to recreational boating, including boats with internal combustion engines and electric propulsion. The company operates in two reportable segments, the sale of electric boats and the rental of electric boats, and generates a substantial portion of its revenue from the USA.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.